ATLANTA, Oct. 1 /PRNewswire-FirstCall/ -- GeoVax Labs, Inc. (OTC Bulletin Board: GOVX), an Atlanta biopharmaceutical company developing human vaccines for diseases caused by HIV-1 (Human Immunodeficiency Virus) and other infectious agents, announced today that its company information will be made available via Standard & Poor's Market Access Program, an information distribution service that enables subscribing publicly traded companies to have their company information disseminated to users of Standard & Poor's Advisor Insight. The company information to be made available through this program includes share price, volume, dividends, shares outstanding, company financial position, and earnings. Standard & Poor's Advisor Insight is an Internet-based research engine used by more than 100,000 investment advisors. A public version of the site is available at http://www.advisorinsight.com.
In addition, information about companies in Standard & Poor's Market Access Program will be available via S&P's Stock Guide database, which is distributed electronically to virtually all major quote vendors. As part of the program, a full description of GeoVax Labs, Inc. will also be published in the Daily News section of Standard Corporation Records, a recognized securities manual for secondary trading in approximately 38 states under their Blue Sky Laws.
About GeoVax Labs, Inc.
GeoVax Labs, Inc. is a biotechnology company, established to develop,
manufacture, license and commercialize human vaccines for diseases caused
by HIV-1 (Human Immunodeficiency Virus) and other infectious agents.
GeoVax's AIDS vaccine technology is the subject of 20 issued or filed
patent applications. GeoVax AIDS vaccines are designed for use in
uninfected people to prevent Acquired Immunodeficiency Disease (AIDS),
caused by the virus known as HIV-1, should the person ever become infected.
GeoVax AIDS vaccines also may be eff
|SOURCE GeoVax Labs, Inc.|
Copyright©2008 PR Newswire.
All rights reserved